For citations:
Mazurov V.I., Gaydukova I.Z., Erdes Sh., Dubinina T.V., Pristrom A.M., Kunder E.V., Soroka N.F., Kastanayan A.A., Povarova T.V., Zhugrova E.S., Plaksina T.V., Shesternya P.A., Kropotina T.V., Antipova O.V., Smolyarchuk E.A., Tciupa O.A., Abdulganieva D.I., Lapshina S.A., Krechikova D.G., Gordeev I.G., Nesmeyanova O.B., Tyrenko V.V., Ilivanova E.P., Strelkova A.V., Eremeeva A.V. Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA. Rheumatology Science and Practice. 2020;58(4):376-386. (In Russ.) https://doi.org/10.47360/1995-4484-2020-376-386
Email this article 